Close

Array Biopharma (ARRY), Pierre Fabre Announce Encorafenib Combo Phase 3 Met Primary Endpoint in BRAF-Mutant Melanoma

Go back to Array Biopharma (ARRY), Pierre Fabre Announce Encorafenib Combo Phase 3 Met Primary Endpoint in BRAF-Mutant Melanoma
Array Biopharma, Inc. (NASDAQ: ARRY) Delayed: 15.10 --0 (-0%)
Previous Close $15.10    52 Week High $7.27 
Open $15.10    52 Week Low $2.39 
Day High $15.10    P/E N/A 
Day Low $15.10    EPS $-0.61 
Volume 1,374